Overview Dividends

(AUPH) Aurinia Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA05156V1022

Immunosuppressant, Lupus, Nephritis, Inhibitor, Autoimmune

Biotechnology
Market Cap in USD: 2,024m
IPO / Inception: 1999-01-26
Return 12m vs S&P 500: 56.7%

EPS (Earnings per Share)

EPS (Earnings per Share) of AUPH over the last years for every Quarter: "2020-12": -0.05, "2021-03": -0.4, "2021-06": -0.37, "2021-09": -0.39, "2021-12": -0.25, "2022-03": -0.27, "2022-06": -0.25, "2022-09": -0.06, "2022-12": -0.18, "2023-03": -0.18, "2023-06": -0.08, "2023-09": -0.09, "2023-12": -0.19, "2024-03": -0.03, "2024-06": 0.01, "2024-09": 0.1, "2024-12": 0.01, "2025-03": 0.16, "2025-06": 0.16, "2025-09": 0.23, "2025-12": 0,
EPS CAGR: 127.38%
EPS Trend: 85.5%
Last SUE: -3.24
Qual. Beats: 0

Revenue

Revenue of AUPH over the last years for every Quarter: 2020-12: 50.03, 2021-03: 0.914, 2021-06: 6.62, 2021-09: 14.667, 2021-12: 23.404, 2022-03: 21.625, 2022-06: 28.191, 2022-09: 55.779, 2022-12: 28.435, 2023-03: 34.409, 2023-06: 41.494, 2023-09: 54.515, 2023-12: 45.095, 2024-03: 50.303, 2024-06: 57.192, 2024-09: 67.771, 2024-12: 59.867, 2025-03: 62.465, 2025-06: 70.008, 2025-09: 73.468, 2025-12: null,
Rev. CAGR: 35.67%
Rev. Trend: 88.0%
Last SUE: 1.02
Qual. Beats: 2

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 48.8%
Value at Risk 5%th 66.3%
Relative Tail Risk -17.43%
Reward TTM
Sharpe Ratio 1.43
Alpha 61.60
CAGR/Max DD 0.43
Character TTM
Hurst Exponent 0.442
Beta 0.660
Beta Downside 0.302
Drawdowns 3y
Max DD 60.80%
Mean DD 28.29%
Median DD 31.58%

Description: AUPH Aurinia Pharmaceuticals November 12, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a Canada-based biopharma focused on high-unmet-need autoimmune disorders. Its flagship product, LUPKYNIS (voclosporin), is an oral calcineurin inhibitor approved for adult patients with active lupus nephritis, and the pipeline includes AUR200, a dual BAFF/APRIL inhibitor targeting broader autoimmune indications.

Key performance indicators as of Q3 2024 show annualized revenue of roughly $120 million, driven primarily by LUPKYNIS sales in the U.S., and a cash runway extending into mid-2026 under current burn rates (~$80 million / year). The company’s market capitalization hovers around $1.2 billion, with a price-to-sales multiple of ~10×, reflecting investor expectations for pipeline de-risking.

Sector-level drivers remain favorable: the global lupus nephritis market is projected to grow at a CAGR of ~7% through 2030, and the broader autoimmune therapeutics space benefits from increasing biologic adoption and payer willingness to reimburse oral alternatives that reduce infusion costs.

For a deeper quantitative assessment of AUPH’s valuation and risk profile, consider reviewing its detailed analyst metrics on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (77.8m TTM) > 0 and > 6% of Revenue (6% = 15.9m TTM)
FCFTA 0.23 (>2.0%) and ΔFCFTA 17.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 136.4% (prev 164.2%; Δ -27.82pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.23 (>3.0%) and CFO 120.1m > Net Income 77.8m (YES >=105%, WARN >=100%)
Net Debt (5.02m) to EBITDA (102.4m) ratio: 0.05 <= 3.0 (WARN <= 3.5)
Current Ratio 5.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (136.0m) change vs 12m ago -6.62% (target <= -2.0% for YES)
Gross Margin 88.81% (prev 87.25%; Δ 1.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 49.37% (prev 40.11%; Δ 9.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 18.73 (EBITDA TTM 102.4m / Interest Expense TTM 4.43m) >= 6 (WARN >= 3)

Altman Z'' 1.89

(A) 0.69 = (Total Current Assets 438.7m - Total Current Liabilities 76.2m) / Total Assets 527.5m
(B) -1.63 = Retained Earnings (Balance) -860.2m / Total Assets 527.5m
warn (B) unusual magnitude: -1.63 — check mapping/units
(C) 0.15 = EBIT TTM 83.0m / Avg Total Assets 538.4m
(D) 1.58 = Book Value of Equity 255.9m / Total Liabilities 161.8m
Total Rating: 1.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 93.59

1. Piotroski 7.50pt
2. FCF Yield 6.85%
3. FCF Margin 45.10%
4. Debt/Equity 0.21
5. Debt/Ebitda 0.05
6. ROIC - WACC (= 14.74)%
7. RoE 21.79%
8. Rev. Trend 87.96%
9. EPS Trend 85.54%

What is the price of AUPH shares?

As of January 07, 2026, the stock is trading at USD 15.44 with a total of 1,091,826 shares traded.
Over the past week, the price has changed by -2.40%, over one month by -1.53%, over three months by +36.40% and over the past year by +84.25%.

Is AUPH a buy, sell or hold?

Aurinia Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy AUPH.
  • Strong Buy: 3
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the AUPH price?

Issuer Target Up/Down from current
Wallstreet Target Price 16.7 8%
Analysts Target Price 16.7 8%
ValueRay Target Price 17.8 15.3%

AUPH Fundamental Data Overview January 05, 2026

Market Cap USD = 2.02b (2.02b USD * 1.0 USD.USD)
P/E Trailing = 27.4107
P/E Forward = 19.9601
P/S = 7.6136
P/B = 5.5328
Beta = 1.437
Revenue TTM = 265.8m USD
EBIT TTM = 83.0m USD
EBITDA TTM = 102.4m USD
Long Term Debt = 78.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 17.4m USD (from shortTermDebt, last quarter)
Debt = 78.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.02m USD (from netDebt column, last quarter)
Enterprise Value = 1.75b USD (2.02b + Debt 78.2m - CCE 351.8m)
Interest Coverage Ratio = 18.73 (Ebit TTM 83.0m / Interest Expense TTM 4.43m)
FCF Yield = 6.85% (FCF TTM 119.9m / Enterprise Value 1.75b)
FCF Margin = 45.10% (FCF TTM 119.9m / Revenue TTM 265.8m)
Net Margin = 29.28% (Net Income TTM 77.8m / Revenue TTM 265.8m)
Gross Margin = 88.81% ((Revenue TTM 265.8m - Cost of Revenue TTM 29.7m) / Revenue TTM)
Gross Margin QoQ = 88.42% (prev 89.84%)
Tobins Q-Ratio = 3.32 (Enterprise Value 1.75b / Total Assets 527.5m)
Interest Expense / Debt = 1.41% (Interest Expense 1.10m / Debt 78.2m)
Taxrate = 1.29% (411.0k / 32.0m)
NOPAT = 81.9m (EBIT 83.0m * (1 - 1.29%))
Current Ratio = 5.76 (Total Current Assets 438.7m / Total Current Liabilities 76.2m)
Debt / Equity = 0.21 (Debt 78.2m / totalStockholderEquity, last quarter 365.8m)
Debt / EBITDA = 0.05 (Net Debt 5.02m / EBITDA 102.4m)
Debt / FCF = 0.04 (Net Debt 5.02m / FCF TTM 119.9m)
Total Stockholder Equity = 357.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.76% (Net Income 77.8m / Total Assets 527.5m)
RoE = 21.79% (Net Income TTM 77.8m / Total Stockholder Equity 357.2m)
RoCE = 19.06% (EBIT 83.0m / Capital Employed (Equity 357.2m + L.T.Debt 78.2m))
RoIC = 22.93% (NOPAT 81.9m / Invested Capital 357.2m)
WACC = 8.19% (E(2.02b)/V(2.10b) * Re(8.45%) + D(78.2m)/V(2.10b) * Rd(1.41%) * (1-Tc(0.01)))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.76%
[DCF Debug] Terminal Value 68.64% ; FCFE base≈83.2m ; Y1≈54.7m ; Y5≈25.0m
Fair Price DCF = 3.48 (DCF Value 458.7m / Shares Outstanding 131.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 85.54 | EPS CAGR: 127.4% | SUE: -3.24 | # QB: 0
Revenue Correlation: 87.96 | Revenue CAGR: 35.67% | SUE: 1.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.19 | Chg30d=+0.033 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=0.94 | Chg30d=+0.173 | Revisions Net=+2 | Growth EPS=+19.6% | Growth Revenue=+16.4%

Additional Sources for AUPH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle